Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Berndt Zipfel, Christine ^a   Michelson, Georg ^b   Dworak, Markus ^c   Mitry, Michael ^a   Löffler, Andrea ^a   Pfützner, Andreas ^a   Forst, Thomas ^a  

^a Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Erythrocyte deformability; Glimepiride; Glucose control; Retinal blood flow; Vildagliptin

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; NITRILE; PYRROLIDINE DERIVATIVE; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTERIOLE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE ELONGATION INDEX; ERYTHROCYTE PARAMETERS; EXPLORATORY RESEARCH; FEMALE; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFECTION; LASER DIFFRACTION; LASER DIFFRACTOSCOPY; LASER DOPPLER FLOWMETRY; LASER FLOWMETER; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RETINA BLOOD FLOW; SHEAR STRESS; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; BLOOD FLOW; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; GERMANY; GLUCOSE BLOOD LEVEL; METABOLISM; MICROCIRCULATION; MIDDLE AGED; PATHOPHYSIOLOGY; RETINA BLOOD VESSEL; TIME;

ADAMANTANE; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; ERYTHROCYTE DEFORMABILITY; FEMALE; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LASER-DOPPLER FLOWMETRY; MALE; METFORMIN; MICROCIRCULATION; MIDDLE AGED; NITRILES; PYRROLIDINES; REGIONAL BLOOD FLOW; RETINAL VESSELS; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875822603     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-59     Document Type: Article

References (55)

1. Forst T, Weber MM, Mitry M, Schondorf T, Forst S, Tanis M, Pfutzner A, Michelson G. Pilot study for the evaluation of morphological and functional changes in retinal blood flow in patients with insulin resistance and/or type 2 diabetes mellitus. J Diabetes Sci Technol 2012, 6:163-168. 3320834, 22401335.
2. Nguyen TT, Kawasaki R, Wang JJ, Kreis AJ, Shaw J, Vilser W, Wong TY. Flicker light-induced retinal vasodilation in diabetes and diabetic retinopathy. Diabetes Care 2009, 32:2075-2080. 10.2337/dc09-0075, 2768208, 19641162.
3. Cuypers MH, Kasanardjo JS, Polak BC. Retinal blood flow changes in diabetic retinopathy measured with the Heidelberg scanning laser Doppler flowmeter. Graefes Arch Clin Exp Ophthalmol 2000, 238:935-941. 10.1007/s004170000207, 11196354.
4. Ritt M, Harazny JM, Ott C, Schneider MP, Schlaich MP, Michelson G, Schmieder RE. Wall-to-lumen ratio of retinal arterioles is related with urinary albumin excretion and altered vascular reactivity to infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine. J Hypertens 2009, 27:2201-2208. 10.1097/HJH.0b013e32833013fd, 19625969.
5. Baumann M, Schwarz S, Kotliar K, von Eynatten M, Trucksaess AS, Burkhardt K, Lutz J, Heemann U, Lanzl I. Non-diabetic chronic kidney disease influences retinal microvasculature. Kidney Blood Press Res 2009, 32:428-433. 10.1159/000264650, 19996611.
6. Awua-Larbi S, Wong TY, Cotch MF, Durazo-Arvizu R, Jacobs DR, Klein BE, Klein R, Lima J, Liu K, Kramer H. Retinal arteriolar caliber and urine albumin excretion: the multi-ethnic study of atherosclerosis. Nephrol Dial Transplant 2011, 26:3523-3528. 10.1093/ndt/gfr095, 3247797, 21398363.
7. Baleanu D, Ritt M, Harazny J, Heckmann J, Schmieder RE, Michelson G. Wall-to-lumen ratio of retinal arterioles and arteriole-to-venule ratio of retinal vessels in patients with cerebrovascular damage. Invest Ophthalmol Vis Sci 2009, 50:4351-4359. 10.1167/iovs.08-3266, 19339746.
8. Harazny JM, Ritt M, Baleanu D, Ott C, Heckmann J, Schlaich MP, Michelson G, Schmieder RE. Increased wall:lumen ratio of retinal arterioles in male patients with a history of a cerebrovascular event. Hypertension 2007, 50:623-629. 10.1161/HYPERTENSIONAHA.107.090779, 17698722.
9. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012, 340:248-255. 10.1124/jpet.111.186866, 22025647.
10. Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, Ito S. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011, 223:133-135. 10.1620/tjem.223.133, 21304217.
11. Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BP, Lessa LM, Malnic G, Girardi AC. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 2011, 301:F355-F363. 10.1152/ajprenal.00729.2010, 21593184.
12. Forst T, Weber MM, Pfutzner A. Cardiovascular benefits of GLP-1-BasedTherapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res 2012, 2012:635472. 3345223, 22577369.
13. Forst T, Michelson G, Ratter F, Weber MM, Anders S, Mitry M, Wilhelm B, Pfutzner A. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med 2012, 29:1115-1118.
14. Betteridge DJ, Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Int J Obes Relat Metab Disord 2005, 48:2477-2481.
15. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011, 34:2072-2077. 10.2337/dc10-2421, 3161271, 21788633.
16. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012, 33:187-215. 10.1210/er.2011-1052, 3528785, 22323472.
17. Shah Z, Pineda C, Kampfrath T, Maiseyeu A, Ying Z, Racoma I, Deiuliis J, Xu X, Sun Q, Moffatt-Bruce S, Villamena F, Rajagopalan S. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 2011, 55:2-9. 10.1016/j.vph.2011.03.001, 21397040.
18. Kunt T, Schneider S, Pfutzner A, Goitom K, Engelbach M, Schauf B, Beyer J, Forst T. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with type 1 diabetes mellitus. Diabetologia 1999, 42:465-471. 10.1007/s001250051180, 10230651.
19. Michelson G, Welzenbach J, Pal I, Harazny J. Functional imaging of the retinal microvasculature by scanning laser Doppler flowmetry. Int Ophthalmol 2001, 23:327-335. 10.1023/A:1014402730503, 11944858.
20. Michelson G, Welzenbach J, Pal I, Harazny J. Automatic full field analysis of perfusion images gained by scanning laser Doppler flowmetry. Br J Ophthalmol 1998, 82:1294-1300. 10.1136/bjo.82.11.1294, 1722437, 9924336.
21. Izzard AS, Rizzoni D, Agabiti-Rosei E, Heagerty AM. Small artery structure and hypertension: adaptive changes and target organ damage. J Hypertens 2005, 23:247-250. 10.1097/00004872-200502000-00002, 15662208.
22. Nguyen TT, Wong TY. Retinal vascular manifestations of metabolic disorders. Trends Endocrinol Metab 2006, 17:262-268. 10.1016/j.tem.2006.07.006, 16890449.
23. Sabanayagam C, Shankar A, Koh D, Chia KS, Saw SM, Lim SC, Tai ES, Wong TY. Retinal microvascular caliber and chronic kidney disease in an Asian population. Am J Epidemiol 2009, 169:625-632.
24. Porta M, Grosso A, Veglio F. Hypertensive retinopathy: there's more than meets the eye. J Hypertens 2005, 23:683-696. 10.1097/01.hjh.0000163131.77267.11, 15775767.
25. Nagaoka T, Yoshida A. Relationship between retinal blood flow and renal function in patients with type 2 diabetes and chronic kidney disease. Diabetes Care 2012, 36:957-961.
26. Schmieder RE, Ritt M. Wall-to-lumen ratio of retinal arterioles: a reproducible, valid and noninvasive approach for evaluation of early arteriolar changes in arterial hypertension in vivo. J Hypertens 2012, 30:1108-1110. 10.1097/HJH.0b013e328353f85a, 22573078.
27. Ritt M, Harazny JM, Ott C, Raff U, Schneider MP, Michelson G, Schmieder RE. Basal nitric oxide activity is an independent determinant of arteriolar structure in the human retinal circulation. J Hypertens 2011, 29:123-129. 10.1097/HJH.0b013e3283406940, 21045732.
28. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 2012, 11:92. 10.1186/1475-2840-11-92, 3471040, 22867630.
29. Bluher M, Kurz I, Dannenmaier S, Dworak M. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes 2012, 3:161-169. 3487174, 23125906.
30. Forst T, Dworak M, Berndt-Zipfel C, Loffler A, Klamp I, Mitry M, Pfutzner A. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the beta cell of patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013, [Epub ahead of print].
31. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res 2012, 9:109-116. 10.1177/1479164111436236, 22337893.
32. Heo KS, Fujiwara K, Abe J. Glucagon-like peptide-1 and its cardiovascular effects. Curr Atheroscler Rep 2012, 14:422-428. 10.1007/s11883-012-0265-9, 22878937.
33. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350. 10.1161/CIRCULATIONAHA.107.739938, 18427132.
34. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001, 102:81-86. 10.1016/S0167-0115(01)00300-7, 11730979.
35. Yin M, Sillje HH, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 2011, 10:85. 10.1186/1475-2840-10-85, 3198901, 21955567.
36. Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, Arakawa M, Jin WL, Kanazawa A, Kawamori R, Fujitani Y, Hirose T, Watada H. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011, 405:79-84. 10.1016/j.bbrc.2010.12.131, 21215253.
37. Murthy SN, Hilaire RC, Casey DB, Badejo AM, McGee J, McNamara DB, Kadowitz PJ, Fonseca VA. The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats. Diab Vasc Dis Res 2010, 7:138-144. 10.1177/1479164109360269, 20382777.
38. Derosa G, Ragonesi PD, Carbone A, Fogari E, D'Angelo A, Cicero AF, Maffioli P. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother 2012, 13:2581-2591. 10.1517/14656566.2012.734499, 23121473.
39. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012, 380:475-483. 10.1016/S0140-6736(12)60691-6, 22748821.
40. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol 2012, 11:6. 10.1186/1475-2840-11-6, 3277488, 22248301.
41. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011, 27(Suppl 3):57-64.
42. Mohandas N, Chasis JA, Shohet SB. The influence of membrane skeleton on red cell deformability, membrane material properties, and shape. Semin Hematol 1983, 20:225-242.
43. Yedgar S, Koshkaryev A, Barshtein G. The red blood cell in vascular occlusion. Pathophysiol Haemost Thromb 2002, 32:263-268. 10.1159/000073578, 13679654.
44. Brown CD, Ghali HS, Zhao Z, Thomas LL, Friedman EA. Association of reduced red blood cell deformability and diabetic nephropathy. Kidney Int 2005, 67:295-300. 10.1111/j.1523-1755.2005.00082.x, 15610255.
45. Shin S, Ku YH, Ho JX, Kim YK, Suh JS, Singh M. Progressive impairment of erythrocyte deformability as indicator of microangiopathy in type 2 diabetes mellitus. Clin Hemorheol Microcirc 2007, 36:253-261.
46. Babu N. Influence of hypercholesterolemia on deformability and shape parameters of erythrocytes in hyperglycemic subjects. Clin Hemorheol Microcirc 2009, 41:169-177.
47. Tsukada K, Sekizuka E, Oshio C, Minamitani H. Direct measurement of erythrocyte deformability in diabetes mellitus with a transparent microchannel capillary model and high-speed video camera system. Microvasc Res 2001, 61:231-239. 10.1006/mvre.2001.2307, 11336534.
48. Keymel S, Heiss C, Kleinbongard P, Kelm M, Lauer T. Impaired red blood cell deformability in patients with coronary artery disease and diabetes mellitus. Horm Metab Res 2011, 43:760-765.
49. Le DC, Khodabandehlou T, Vimeux M. Relationship between hemorheological and microcirculatory abnormalities in diabetes mellitus. Diabete Metab 1994, 20:401-404.
50. Zimny S, Dessel F, Ehren M, Pfohl M, Schatz H. Early detection of microcirculatory impairment in diabetic patients with foot at risk. Diabetes Care 2001, 24:1810-1814. 10.2337/diacare.24.10.1810, 11574447.
51. Cicco G, Pirrelli A. Red blood cell (RBC) deformability, RBC aggregability and tissue oxygenation in hypertension. Clin Hemorheol Microcirc 1999, 21:169-177.
52. Forst T, Weber MM, Lobig M, Lehmann U, Muller J, Hohberg C, Friedrich C, Fuchs W, Pfutzner A. Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus. Clin Sci (Lond) 2010, 119:345-351.
53. Tsuda K. Adiponectin and membrane fluidity of erythrocytes in normotensive and hypertensive men. Obesity (Silver Spring) 2006, 14:1505-1510.
54. Tsuda K, Nishio I. Membrane fluidity and hypertension. Am J Hypertens 2003, 16:259-261. 10.1016/S0895-7061(02)03257-0, 12620708.
55. Zicha J, Kunes J, Devynck MA. Abnormalities of membrane function and lipid metabolism in hypertension: a review. Am J Hypertens 1999, 12:315-331. 10.1016/S0895-7061(98)00178-2, 10192236.